<p>, /PRNewswire/ -- Arna Pharma Inc 和 Slate Run Pharmaceuticals 宣佈他們已簽署諒解備忘錄，計劃創建一個以美國為基地的專業製藥合資企業，專注於品牌產品、505(b)(2) 藥物和專業仿製藥。</p>
<p>該合資企業將 Arna Pharma 的開發能力和產品組合擴展戰略與 Slate Run Pharmaceuticals 在美國的商業、監管和供應鏈基礎設施相結合。</p>
<p>&#34;這標誌着 Arna Pharma 的一個重要里程碑，也是我們長期戰略向前邁出的重要一步，&#34; Arna Pharma Inc 高級副總裁 Ram Iyer 説。&#34;通過將 Arna 的開發專業知識與 Slate Run 經過驗證的美國商業和運營基礎設施相結合，我們創建了一個獨特的平台，能夠在高價值治療領域擴展專業仿製藥，並加速市場準入、報銷和醫生參與。&#34;</p>
<p>Slate Run Pharmaceuticals 成立於 2014 年，已在美國建立了強大的市場基礎，擁有一支經驗豐富的商業和監管團隊。該合資企業將能夠高效地在美國市場擴展品牌和專業產品。</p>
<p>&#34;我們很高興能夠團結我們的組織，共同開啓這一新篇章，&#34; Slate Run Pharmaceuticals 首席執行官 Michael Plessinger 説。&#34;這種結合增強了我們執行的能力，擴展了我們的產品組合，並繼續作為行業的可信賴美國合作伙伴。&#34;</p>
<p>兩家組織的領導層將緊密合作，以確保無縫整合，保持運營連續性，並遵循最高標準的監管合規、產品質量和患者護理。</p>
<p>Arna Pharma Inc 和 Slate Run Pharmaceuticals 歡迎與戰略合作伙伴、投資者、許可方和投資組合公司進行接觸，感興趣的各方可以與合併後的組織合作，共同執行其增長戰略，建立領先的美國專業製藥平台。</p>
<p>如需更多信息，請聯繫：</p>
<ul>
<li><strong><em>Arna Pharma Inc.:</em></strong> Ram Iyer, [email protected]</li>
<li><strong><em>Slate Run Pharmaceuticals LLC</em></strong> : Mike Plessinger, [email protected]</li>
</ul>
<p><strong>關於 Arna Pharma Inc.</strong></p>
<p>美國業務於 2024 年啓動，旨在創造一個更健康的世界，Arna Pharma Inc 將專利級創新與智能、可持續的商業實踐相結合。由行業專家創立，專注於創新和患者結果，我們對質量和誠信的承諾驅動我們提供安全、有效和可靠的治療方案。</p>
<p>作為一家全面整合的製藥組織，Arna Pharma Inc 提供從配方開發和生產到全球營銷和商業化的端到端能力。我們的產品組合強調小眾劑型和針對罕見和被忽視疾病的治療，反映了我們以專業化為重點解決未滿足醫療需求的使命。</p>
<p><strong>關於 Slate Run Pharmaceuticals:</strong></p>
<p>Slate Run Pharmaceuticals 成立於 2014 年，在美國仿製藥市場建立了強大且不斷擴展的存在。公司由一支經驗豐富的領導團隊領導，團隊成員在商業運營、監管事務、質量和供應鏈管理方面擁有超過 200 年的行業經驗。Slate Run 的團隊直接參與了廣泛的仿製藥組合的選擇、FDA 批准、商業化和供應，涵蓋多個治療領域。</p>
<p>目前，Slate Run 市場上有超過 30 個產品系列，服務於包括批發商、分銷商、藥店和醫療服務提供者在內的美國客户。通過嚴格的產品組合開發、戰略製造合作伙伴關係以及對監管合規和供應可靠性的承諾，Slate Run 致力於擴大患者對高質量、可負擔藥物的獲取，同時推動可持續增長。</p>
<p>來源：Slate Run Pharmaceuticals; Arna Pharma Inc。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI2Jk5ld3NJdGVtSWQ9Q0w5NjcxNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjYxMzAwUFJfTkVXU19VU1BSX19fX19DTDk2NzE0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI2Jk5ld3NJdGVtSWQ9Q0w5NjcxNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjYxMzAwUFJfTkVXU19VU1BSX19fX19DTDk2NzE0"/></p>

SLRX

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

<p>Arna Pharma Inc. 和 Slate Run Pharmaceuticals 簽署了一份諒解備忘錄（MOU），旨在建立一個合資企業，以創建一個規模化的美國專業製藥平台。此次合作將利用 Arna 的開發能力和 Slate Run 的商業及監管基礎設施，專注於品牌產品、505(b)(2) 藥物和專業仿製藥。合資企業預計將增強市場準入，並加速在高價值治療領域推出專業仿製藥。兩家公司領導層將確保無縫整合，並維護監管合規性和產品質量標準</p>

<p>, /PRNewswire/ -- Arna Pharma Inc <strong>.</strong> and Slate Run Pharmaceuticals announced they have signed an MOU to create a scaled-up U.S.-based specialty pharmaceutical joint venture focused on branded products, 505(b)(2) medicines, and specialized generics.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Arna Pharma Inc 和 Slate Run Pharmaceuticals 宣佈他們已簽署諒解備忘錄，計劃創建一個以美國為基地的專業製藥合資企業，專注於品牌產品、505(b)(2) 藥物和專業仿製藥。</p>
</div><p>The joint venture brings together Arna Pharma's development capabilities and portfolio expansion strategy with Slate Run Pharmaceuticals' established U.S. commercial, regulatory, and supply chain infrastructure.</p>
<div class="lb-trans"><p>該合資企業將 Arna Pharma 的開發能力和產品組合擴展戰略與 Slate Run Pharmaceuticals 在美國的商業、監管和供應鏈基礎設施相結合。</p>
</div><p>&#34;This represents a significant milestone for Arna Pharma and a powerful step forward in our long-term strategy,&#34; said Ram Iyer, Senior Vice President of Arna Pharma Inc. &#34;By combining Arna's development expertise with Slate Run's proven U.S. commercial and operational infrastructure, we have created a platform that is uniquely positioned to expand specialized generics in high-value therapeutic segments and accelerate market access, reimbursement, and physician engagement.&#34;</p>
<div class="lb-trans"><p>&#34;這標誌着 Arna Pharma 的一個重要里程碑，也是我們長期戰略向前邁出的重要一步，&#34; Arna Pharma Inc 高級副總裁 Ram Iyer 説。&#34;通過將 Arna 的開發專業知識與 Slate Run 經過驗證的美國商業和運營基礎設施相結合，我們創建了一個獨特的平台，能夠在高價值治療領域擴展專業仿製藥，並加速市場準入、報銷和醫生參與。&#34;</p>
</div><p>Founded in 2014, Slate Run Pharmaceuticals has built a strong U.S. footprint, consisting of an experienced commercial and regulatory team. The joint venture will be well-positioned to scale branded and specialized products efficiently across the U.S. market.</p>
<div class="lb-trans"><p>Slate Run Pharmaceuticals 成立於 2014 年，已在美國建立了強大的市場基礎，擁有一支經驗豐富的商業和監管團隊。該合資企業將能夠高效地在美國市場擴展品牌和專業產品。</p>
</div><p>&#34;We are excited to unite our organizations and begin this next chapter together,&#34; said Michael Plessinger, CEO of Slate Run Pharmaceuticals. &#34;This combination strengthens our ability to execute, expand our portfolio, and continue to serve as a trusted U.S. partner for the industry.&#34;</p>
<div class="lb-trans"><p>&#34;我們很高興能夠團結我們的組織，共同開啓這一新篇章，&#34; Slate Run Pharmaceuticals 首席執行官 Michael Plessinger 説。&#34;這種結合增強了我們執行的能力，擴展了我們的產品組合，並繼續作為行業的可信賴美國合作伙伴。&#34;</p>
</div><p>Leadership from both organizations will work closely to ensure seamless integration, maintain operational continuity, and uphold the highest standards of regulatory compliance, product quality, and patient care.</p>
<div class="lb-trans"><p>兩家組織的領導層將緊密合作，以確保無縫整合，保持運營連續性，並遵循最高標準的監管合規、產品質量和患者護理。</p>
</div><p>Arna Pharma Inc and Slate Run Pharmaceuticals welcome engagement with strategic partners, investors, licensors, and portfolio companies interested in collaborating with the combined organization as it executes its growth strategy and builds a leading U.S. specialty pharmaceutical platform.</p>
<div class="lb-trans"><p>Arna Pharma Inc 和 Slate Run Pharmaceuticals 歡迎與戰略合作伙伴、投資者、許可方和投資組合公司進行接觸，感興趣的各方可以與合併後的組織合作，共同執行其增長戰略，建立領先的美國專業製藥平台。</p>
</div><p>For more information please contact:</p>
<div class="lb-trans"><p>如需更多信息，請聯繫：</p>
</div><ul>
<li><strong><em>Arna Pharma Inc.:</em></strong> Ram Iyer, [email protected]</li>
<li><strong><em>Slate Run Pharmaceuticals LLC</em></strong> : Mike Plessinger, [email protected]</li>
</ul>
<div class="lb-trans"><ul>
<li><strong><em>Arna Pharma Inc.:</em></strong> Ram Iyer, [email protected]</li>
<li><strong><em>Slate Run Pharmaceuticals LLC</em></strong> : Mike Plessinger, [email protected]</li>
</ul>
</div><p><strong>About Arna Pharma Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Arna Pharma Inc.</strong></p>
</div><p>The USA Operation started in 2024 with a vision to create a healthier world, Arna Pharma Inc. blends patent-level innovation with smart, sustainable business practices. Founded by industry experts with a strong focus on innovation and patient outcomes, our commitment to quality and integrity drives us to deliver safe, effective, and reliable therapies.</p>
<div class="lb-trans"><p>美國業務於 2024 年啓動，旨在創造一個更健康的世界，Arna Pharma Inc 將專利級創新與智能、可持續的商業實踐相結合。由行業專家創立，專注於創新和患者結果，我們對質量和誠信的承諾驅動我們提供安全、有效和可靠的治療方案。</p>
</div><p>As a fully integrated pharmaceutical organization, Arna Pharma Inc. offers end-to-end capabilities, from formulation development and manufacturing to global marketing and commercialization. Our portfolio emphasizes niche dosage forms and treatments for rare and underserved diseases, reflecting our mission to address unmet medical needs with specialized focus on Respiratory Indications.</p>
<div class="lb-trans"><p>作為一家全面整合的製藥組織，Arna Pharma Inc 提供從配方開發和生產到全球營銷和商業化的端到端能力。我們的產品組合強調小眾劑型和針對罕見和被忽視疾病的治療，反映了我們以專業化為重點解決未滿足醫療需求的使命。</p>
</div><p><strong>About Slate Run Pharmaceuticals:</strong></p>
<div class="lb-trans"><p><strong>關於 Slate Run Pharmaceuticals:</strong></p>
</div><p>Founded in 2014, Slate Run Pharmaceuticals has built a strong and expanding presence in the U.S. generic pharmaceutical market. The company is led by a seasoned leadership team with over 200 years of combined industry experience across commercial operations, regulatory affairs, quality, and supply chain management. Slate Run's team has been directly involved in the selection, FDA approval, commercialization, and supply of a broad portfolio of generic pharmaceuticals spanning multiple therapeutic areas.</p>
<div class="lb-trans"><p>Slate Run Pharmaceuticals 成立於 2014 年，在美國仿製藥市場建立了強大且不斷擴展的存在。公司由一支經驗豐富的領導團隊領導，團隊成員在商業運營、監管事務、質量和供應鏈管理方面擁有超過 200 年的行業經驗。Slate Run 的團隊直接參與了廣泛的仿製藥組合的選擇、FDA 批准、商業化和供應，涵蓋多個治療領域。</p>
</div><p>Today, Slate Run markets more than 30 product families and serves customers across the U.S., including wholesalers, distributors, pharmacies, and healthcare providers. Through disciplined portfolio development, strategic manufacturing partnerships, and a commitment to regulatory compliance and supply reliability, Slate Run is dedicated to expanding patient access to high-quality, affordable medications while driving sustainable growth.</p>
<div class="lb-trans"><p>目前，Slate Run 市場上有超過 30 個產品系列，服務於包括批發商、分銷商、藥店和醫療服務提供者在內的美國客户。通過嚴格的產品組合開發、戰略製造合作伙伴關係以及對監管合規和供應可靠性的承諾，Slate Run 致力於擴大患者對高質量、可負擔藥物的獲取，同時推動可持續增長。</p>
</div><p>SOURCE Slate Run Pharmaceuticals; Arna Pharma Inc.</p>
<div class="lb-trans"><p>來源：Slate Run Pharmaceuticals; Arna Pharma Inc。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI2Jk5ld3NJdGVtSWQ9Q0w5NjcxNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjYxMzAwUFJfTkVXU19VU1BSX19fX19DTDk2NzE0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CL96714&amp;Transmission_Id=202602261300PR_NEWS_USPR_____CL96714&amp;DateId=20260226"/></p>

13:00 ETArna Pharma Inc. and Slate Run Pharmaceuticals to form a Joint Venture to Create Scaled-Up U.S. Specialty Pharmaceutical Platform

prnewswire

Salarius Pharmaceuticals

標普全球醫療股指數 ETF - iShares

Verona制藥

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - SPDR

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

Sarepta醫療

福泰制藥

醫療業 ETF - Vanguard

Armata Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Arna Pharma Inc.與 Slate Run Pharmaceuticals 將成立合資企業，旨在打造一個擴大規模的美國專業製藥平台